AKT1 and breast cancer: In addition, this study also provides targeting reference drugs for the core prognostic genes to provide a reference for clinical practice, and the accuracy of drug targeting genes was verified by basic experiments and elucidates in detail that Vemurafenib suppresses BC by targeting the PI3K/AKT signaling pathway to inhibit the immune escape biomarker BCL2A1.